SPECTROPHOTOMETRIC METHODS FOR DETERMINATION OF SOFOSBUVIR AND DACLATASVIR IN PURE AND DOSAGE FORMS

Authors

  • MONIR Z. SAAD Chemistry Department, Faculty of Science, Zagazig University, Zagazig, 44519, Egypt
  • ATEF AMER Chemistry Department, Faculty of Science, Zagazig University, Zagazig, 44519, Egypt
  • KHALED ELGENDY Chemistry Department, Faculty of Science, Zagazig University, Zagazig, 44519, Egypt
  • BASEM ELGENDY Chemistry Department, Faculty of Science, Zagazig University, Zagazig, 44519, Egypt

DOI:

https://doi.org/10.22159/ijap.2021v13i6.42564

Keywords:

Sofosbuvir, Daclatasvir, Spectrophotometry, Cerium(IV), dyes, Method validation, Dosage forms

Abstract

Objective: Two simple, sensitive and accurate spectrophotometric methods have been developed for the determination of sofosbuvir (SOF) and daclatasvir (DAC) in pure forms and pharmaceutical formulations.

Methods: The proposed methods are based on the oxidation of SOF and DAC by a known excess of cerium(IV) ammonium nitrate in sulphuric acid medium followed by determination of unreacted cerium(IV) by adding a fixed amount of indigo carmine (IC) and alizarin red S (ARS) dyes followed by measuring the absorbance at 610 and 360 nm, respectively. The experimental conditions affecting the reaction were studied and optimized.

Results: The beer’s law was obeyed in the concentration ranges of 0.2-3.0, 0.2-4.0 for SOF and 0.5-4.5 and 0.5-5.0 μg/ml for DAC using IC and ARS methods, respectively with a correlation coefficient ≥ 0.9991. The calculated molar absorptivity values are 2.354 × 104, 1.933 × 104 for SOF and 1.786 × 104 and 2.015 × 104 L/mol.cm for DAC using IC and ARS methods, respectively u. The limits of detection and quantification are also reported. Intra-day and inter-day precision and accuracy of the methods have been evaluated.

Conclusion: The methods were successfully applied to the assay of SOF and DAC in tablets and the results were statistically compared with those of the reference method by applying Student’s t-test and F-test. No interference was observed from the common tablet excipients. The accuracy and reliability of the methods were further ascertained by performing recovery studies using the standard addition method.

Downloads

Download data is not yet available.

References

"FDA approves Sovaldi for chronic hepatitis C". FDA New Release. U.S. Food and Drug Administration, 6th December, 2013.

"Essential Medicines WHO Model List, 19th edition, April 2015" (PDF). World Health Organization, 2015.

Rezk MR, Bendas ER, Basalious EB, Karim IA. Development and validation of sensitive and rapid UPLC–MS/MS method for quantitative determination of daclatasvir in human plasma: application to a bioequivalence study. J Pharm Biomed Anal 2016;128:61-6.

Eldin AS, Azab SM, Shalaby A, El-Maamly M. The Development of a new validated HPLC and spectrophotometric methods for the simultaneous determination of daclatasvir and sofosbuvir: antiviral drugs. J Pharm Pharmacol Res 2017;1: 028-42.

Bandla J, Ganapaty S, Development and validation of stability indicating RP-HPLC method for the simultaneous estimation of sofosbuvir and daclatasvir dihydrochloride in bulk drug and pharmaceutical dosage form. Saudi J Med Pharm Sci 2018;4:542-51.

Zaman B, Siddique F, Hassan W. RP-HPLC Method for Simultaneous determination of sofosbuvir and ledipasvirin tablet dosage form and its application to in vitro dissolution studies. Chromatographia 2016;79:1605–13.

Nekkala K, Shanmukha Kumar JV, Ramachandran D, Analytical method development and validation for the simultaneous estimation of sofosbuvir and velpatasvir drug product by reverse phase high performance liquid chromatography method. Asian J Pharm an Clin Res 2018;11:164-8.

Sumathi K, Thamizhvanan K, Vijayraj S. Development and validation of stability indicating RP-HPLC method for the estimation of daclatasvir in bulk and formulation. Der Pharm Lett 2016;8:107-13.

Ashok Chakravarthy V, Sailaja BBV, Method development and validation of assay and dissolution methods for the estimation of daclatasvir in tablet dosage forms by reverse phase HPLC. Eur J Pharm Med Res 2016;3:356-64.

El Sheikh R, Hassan WS, Gouda AA, Kamal MM. A rapid stability-indicating HPLC method for determination of daclatasvir in pure form and tablets. Int J Pharm Sci Rev Res. 2018;51:98-103.

Nannetti G, Messa L, Celegato M, Pagni S, Basso M, Parisi SG, Palu G, Loregain A, Development and validation of a simple and robust HPLC method with UV detection for quantification of the hepatitis C virus inhibitor daclatasvir in human plasma. J Pharm Biomed Anal 2017;134:275-81.

Chakravarthy VA, Sailaja BBV. Method development and validation of assay and dissolution methods for the estimation of daclatasvir in tablet dosage forms by reverse phase HPLC. Eur J Pharm Med Res. 2016;3:356-64.

Moustapha ME, El‑Gamal RM, Belal FF. Two novel UPLC methods utilizing two different analytical columns and different detection approaches for the simultaneous analysis of velpatasvir and sofosbuvir: application to their co-formulated tablet. BMC Chem 2019;13:118.

Shaik JO, Muniappan M, Manikanta KA, Muralidaran K, Ramulu Y, Venkat R., estimation of sofosbuvir with validated Ultra High Performance Liquid Chromatographic (UHPLC) method in its bulk and formulations. Der Pharm Sinica 2017;8:10-15.

Rezk MR, Basalious EB, Karim IA. Development of a sensitive UPLC-ESIMS/MS method for quantification of sofosbuvir and its metabolite, GS-331007, in human plasma: Application to a bioequivalence study. J Pharm Biomed Anal 2015;114:97-104.

Chenwei P, Yongping C, Weilai C, Guangyao Z. Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC–MS/MS and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Scince. 2016;1008:255-59.

Ariaudo A, Favata F, De Nicolò A, Simiele M, Paglietti L, Boglione L, Cardellino CS, Carcieri C, Di Perri G, Avolio A. A UHPLC–MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, together in human plasma. J Pharm Biomed Anal. 2016;5:369-75.

Azab SM, Fekry AM. Electrochemical design of a new nanosensor based on cobalt nanoparticles, chitosan and MWCNT for the determination of daclatasvir: a hepatitis C antiviral drug. RSC Advances. 2017;7:1118-26.

Eissa MS, Fayed AS, Hegazy MA, Kamel EB. Spectrophotometric analysis for simultaneous determination of the new antiviral drug combination: daclatasvir/ sofosbuvir in their pure form and pharmaceutical preparation, Res J Pharm Tech. 2020;13:5939-46.

Vikas K, Sachin G, Omprakash B. Development, validation and stability study of UV spectrophotometric method for determination of daclatasvir in bulk and pharmaceutical dosage forms. Int J ChemTech Res 2017;10:281-87.

Jeevana JB, Padmaja G. UV spectrophotometric method for estimation of new drug, daclatasvir dihydrochloride. Int Res J Pharm 2016;7:1-3.

Ashok CV, Sailaja BBV, Praveen KA. Method development and validation of ultraviolet-visible spectroscopic method for the estimation of hepatitis-c drugs - daclatasvir and sofosbuvir in active pharmaceutical ingredient form, Asian J Pharm Clin Res. 2016;9:61-6.

Kishore MS, Rambabu C., Development and validation of UV spectrophotometric method for the estimation of sofosbuvir and ledipasvir in combined pharmaceutical dosage forms, Int J ChemTech Res 2019;12:33-40.

Rathod SM, Patel PU, Development and validation for simultaneous estimation of sofosbuvir and daclatasvir dihydrochloride in pharmaceutical dosage form by ratio derivative and dual wavelength methods, IJPQA, 2020;11:25-31.

Nasr ZA, Said NS, Abdel-Razeq SA, Uv spectrophotometric methods for determination of sofosbuvir in pure form and pharmaceutical dosage forms in presence of its alkaline degradate, Asian J Appl Chem Res 2020;5:12-25.

Shalaby A, El-Maamly M, Abdel-Gawad FM, Azab SM, Eldin AS. Spectrophotometric determination of daclatasvir dihydrochloride by ion-pair reaction with bromophenol blue, bromothymol blue and bromocresol green, Chem Res J 2017;2:163-73.

Abdellatef HA, El-Henawee MM, El-Sayed HM, Ayad MM, Spectrophotometric and spectrofluorimetric methods for analysis of acyclovir and acebutolol hydrochloride. Spectrochim Acta A. 2006;65:997-9.

Krebs A, Starczewska B, Puzanowska-Tarasiewicz H, Sledz J. Spectrophotometric determination of olanzapine by its oxidation with N-bromosuccinimide and cerium(IV) sulfate. Anal Sci. 2006;22:829-33.

El-Didamony AM, Erfan EAH, Utilization of oxidation reactions for the spectrophotometric determination of captopril using brominating agents, Spectrochim Acta A. 2010;75: 1138-45.

El Shiekh R, Amin AS, Hafez EM, Gouda AA, Spectrophotometric estimation of vardenafil HCl and tadalafil in pure forms and tablets using cerium(IV) ammonium sulphate. Der Pharm Lett. 2016; 8: 153-65

El-Didamony AM, Hassan WS, Spectrophotometric and fluorimetric methods for determination of naltrexone in urine, serum and tablets by oxidation with cerium (IV). J Chil Chem Soc. 2012;57:1404-8.

El Sheikh R, Hassan WS, Gouda AA, Al Owairdhi AA.. Validated and sensitive spectrophotometric methods for estimation of rizatriptan benzoate in pharmaceutical formulations using cerium (IV) sulphate. Res J Pharm Tech. 2019;12:2123-30.

El Sheikh R, Hassan WS, Gouda AA, El Gabry MM. Utility of cerium (IV) ammonium sulphate as oxidizing agent for spectrophotometric assay of oxybutynin hydrochloride in pharmaceutical preparations. Int J Res Pharmacy Pharm Sci 2018;3:09-16.

El Sheikh R, Hassan WS, Gouda AA, Abdel Fattah GM. Validated spectrophotometric methods for determination of donepezil hydrochloride in pharmaceutical formulations based on redox reaction with cerric(IV) ammonium sulphate, Int J Pharm Sci Rev Res. 2018;52:66-74.

El Sheikh R, Gouda AA, Sadek LA. New spectrophotometric method for determination of Aripiprazole in pure form and pharmaceutical formulations using ceric (IV) ammonium sulphate. Int J Res Pharmacy Pharm Sci 2018;3:259-267.

Jeffery GH, Bassett J, Mendham J, Denney RC, Titrimetric analysis. In Vogel’s a text book of quantitative inorganic analysis, 5th Ed., ELBS: London, 1989; pp. 308.

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2(R1), Complementary Guideline on Methodology, London, November 2005.

Miller JN, Miller JC, “Statistics and chemometrics for analytical chemistry” 5th ed., Prentice Hall, England, 2005.

Published

26-08-2021

How to Cite

Z. SAAD, M., AMER, A., ELGENDY, K., & ELGENDY, B. (2021). SPECTROPHOTOMETRIC METHODS FOR DETERMINATION OF SOFOSBUVIR AND DACLATASVIR IN PURE AND DOSAGE FORMS. International Journal of Applied Pharmaceutics, 13(6). https://doi.org/10.22159/ijap.2021v13i6.42564

Issue

Section

Original Article(s)